Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Theravance Biopharma (TBPH) Long-Term Debt Issuances (2020)

Theravance Biopharma (TBPH) has disclosed Long-Term Debt Issuances for 1 consecutive years, with $380.0 million as the latest value for Q1 2020.

  • On a quarterly basis, Long-Term Debt Issuances changed N/A to $380.0 million in Q1 2020 year-over-year; TTM through Dec 2020 was $380.0 million, a N/A change, with the full-year FY2020 number at $380.0 million, changed N/A from a year prior.
  • Long-Term Debt Issuances was $380.0 million for Q1 2020 at Theravance Biopharma.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $380.0 million in Q1 2020 to a low of $380.0 million in Q1 2020.